Phase III, randomized trial comparing clinical outcomes between patients with moderate-to-severe chronic plaque psoriasis receiving adalimumab reference product (RP) continuously vs those who switched between BI 695501 and adalimumab RP-MedSci.cn

Phase III, randomized trial comparing clinical outcomes between patients with moderate-to-severe chronic plaque psoriasis receiving adalimumab reference product (RP) continuously vs those who switched between BI 695501 and adalimumab RP

Menter, A; McCabe, D; Lang, B; Schaible, J; Eduru, SK

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021; 85 (3): AB140

科室
- - 订阅+
  - 更多科室
工具
服务